相关临床试验
7
4 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1964
进行中（未招募）
2
28.6%
尚未招募
2
28.6%
招募中
3
42.9%
暂无批准数据
- Six health systems received grants ranging from $185,000 to $250,000 to optimize molecular testing pathways and biomarker-driven treatment selection in metastatic colorectal cancer. - The initiative, launched in collaboration with Pfizer and ASCO, addresses persistent gaps in testing for RAS, BRAF, HER2, and MSI/MMR biomarkers aligned with NCCN guidelines. - Funded projects will leverage ASCP's Performance and Diagnostic Insights platform for real-time data analytics to improve turnaround times and care coordination. - With over 150,000 new colorectal cancer cases annually in the U.S., the program aims to generate scalable best practices for precision oncology nationwide.
- Gary R. Morrow, PhD, MS, a leader at the University of Rochester Wilmot Cancer Institute, died on July 7, 2026, at age 82 from pneumonia complications after living with prostate cancer for 16 years. - His research helped establish the need for anti-emetic drugs to control chemotherapy-induced nausea and vomiting, ranked among the top five advances in cancer care over the past 50 years by ASCO. - Over nearly five decades, Morrow brought in $100 million in funding and built the URCC NCORP network, bringing supportive care research directly to patients in their communities. - He trained a generation of leaders in supportive oncology, including Karen Mustian, Supriya Mohile, Charles Kamen, and Michelle Janelsins, who now carry forward his legacy.
- ASCO released its first formal guideline on circulating tumor DNA (ctDNA) testing, approved by an expert panel on November 18, 2025, and published in JCO Oncology Practice. - The guideline recommends ctDNA testing when tissue biopsy is infeasible, results are needed within a clinically actionable timeframe, or a drug's approved indication requires blood-based testing. - ctDNA testing is positioned as a complementary tool, not a replacement for standard-of-care testing such as tissue biopsy or imaging, and should only be offered when results can inform clinical decision-making. - Concentration-based ctDNA measures are not endorsed as surrogates for disease burden outside clinical trials, and cancer type–specific guidelines are anticipated as the evidence base matures.
- ASCO convened a multidisciplinary panel to create new evidence-based recommendations for systemic treatment across all thyroid cancer subtypes, including anaplastic, medullary, and well-differentiated disease. - The guidelines emphasize upfront molecular testing for advanced or aggressive thyroid cancer to identify actionable targets such as RET alterations and BRAF/MEK mutations. - For anaplastic thyroid cancer, the combination of dabrafenib/trametinib with pembrolizumab immunotherapy has shown remarkable results, transforming outcomes in a historically dismal disease. - Treatment selection and sequencing should be coordinated through a multidisciplinary tumor board, with a move toward personalized use of radioiodine and potential reduction in surgical intervention through targeted agents.
- ASCO and the Association for Clinical Oncology issued a critical drug supply warning after members reported severe disruptions to ifosfamide (Ifex) supply, with some practices holding less than a few weeks of inventory. - The shortage stems from a Baxter-contracted manufacturer in Germany halting production due to inspection-related issues, while alternate manufacturers Fresenius Kabi and Hikma have placed products on allocation. - No direct substitute exists for ifosfamide, which is used most often in pediatric sarcoma, testicular cancer, and lymphoma, and the shortage may persist until at least October 2026. - The FDA plans to temporarily allow importation of ifosfamide from overseas manufacturers, while guidance outlines supply, substitution, and conservation strategies organized into a three-tier, risk-based system.
- ASCO updated its Living Guideline for stage IV NSCLC with driver alterations, adding repotrectinib and zongertinib as new treatment options based on the TRIDENT-1 and Beamion LUNG-1 trials. - Repotrectinib, a TRK/ROS1/ALK TKI, achieved a 59% confirmed objective response rate in TKI-naive NTRK fusion–positive solid tumors and showed impressive intracranial activity. - Zongertinib, an oral HER2-selective TKI, produced a 76% confirmed objective response rate in treatment-naive HER2-mutant NSCLC, with a median progression-free survival of 14.5 months. - The updates signal a shift toward next-generation targeted therapies designed for upfront use and for overcoming resistance, expanding options for patients with rare driver alterations.
- Tumor-agnostic drugs and basket trials are expanding clinical trial access for people with rare cancers who historically lacked standard treatment roadmaps and trial options. - In a basket trial spanning 17 cancer types, the NTRK inhibitor larotrectinib shrank tumors in 75% of patients and prevented progression for at least one year in about 55%. - Larotrectinib became the second tumor-agnostic targeted therapy approved by the FDA based on basket trial results, offering children with CIFS a way to potentially avoid harsh chemotherapy and surgery. - The American Cancer Society's ACS ACTS program uses artificial intelligence to match patients with trials and address barriers such as low enrollment among Black, Hispanic, rural, and older patients.
- The American Heart Association and American Society of Clinical Oncology issued a joint scientific statement on defining cardiovascular endpoints in oncology trials, published in the Journal of Clinical Oncology and Circulation. - The statement provides a framework for asking cardiovascular safety questions before oncology trials begin, addressing a critical gap in current trial design. - Experts emphasize that traditional endpoints like MACE and mortality may slow innovation, while surrogate biomarkers such as MRD and ctDNA can accelerate decision-making. - The FDA's January 2026 MRD guidance in multiple myeloma was highlighted as a turning point, enabling transformative therapy decisions at 12 months instead of seven years.
- Pre-biopsy MRI, standard of care in Europe, Canada, Australia, and the U.K., was used in only about one-third of U.S. prostate cancer cases in 2022 despite strong guideline recommendations. - The 2018 PRECISION trial and subsequent studies demonstrate that MRI before biopsy detects more clinically significant cancer while reducing overdiagnosis of low-grade disease. - Up to 70% of new U.S. prostate cancer diagnoses are low-grade and require no treatment, yet as many as 50% or more of men with such disease still receive intervention. - Experts cite knowledge deficits, variable MRI quality, financial incentives favoring systematic biopsies, and access disparities as key barriers to broader pre-biopsy MRI adoption in the United States.
- Sen. Ron Johnson convened a June 3 hearing alleging mRNA COVID vaccines may cause cancer and that research on safety signals has been systematically suppressed by federal health agencies. - Witnesses including Dr. Angus Dalgleish and Dr. Wafik El-Deiry argued for scientific freedom to investigate vaccine safety concerns, while ASCO's Dr. Julie Gralow stated there is no clinical evidence linking mRNA vaccines to cancer. - Sen. Richard Blumenthal countered by citing NCI conclusions and a JAMA study of nearly 30 million people showing vaccinated individuals were less likely to die from cancer four years post-vaccination. - The hearing reflects a broader political conflict, with both sides accusing each other of suppressing science amid Trump administration cuts to cancer research and reported FDA study blockages.
